FEMALES - menstruating: Follicular phase 2.4 - 12.6 mIU/mL Ovulation phase 14.0 - 95.6 mIU/mL Luteal phase 1.0 - 11.4 mIU/mL Postmenopause 7.7 - 58.5 mIU/mL MALES: 1.7 - 8.6 mIU/mL AGE MALES FEMALES Prepubertal <0.5 mIU/mL <0.5 mIU/mL Tanner II 0.2-2.8 mIU/mL 0.1-4.1 mIU/mL Tanner III 1.2-3.9 mIU/mL 0.2-9.2 mIU/mL Tanner IV 0.9-4.4 mIU/mL 0.7-8.6 mIU/mL Tanner V 1.8-5.3 mIU/mL 0.5-7.3 mIU/mL

The assay is unaffected by icterus (bilirubin is less than 66 mg/dL), hemolysis (Hb is less than 1000 mg/dL), lipemia (Intralipid is less than 1900 mg/dL) and biotin is less than 50 ng/mL (criterion: recovery within plus or minus 10% of initial value). In patients receiving therapy with high biotin doses (i.e. is greater than 5 mg/day) no sample should be taken until at least 8 hours after the last biotin administration. No interference was observed from rheumatoid factors up to a concentration of 1500 U/mL. No high dose hook effect at LH concentrations of up to 1150 mIU/mL In vitro tests were performed on 17 commonly used pharmaceuticals. No interference with the assay was found. Samples of neonates have not been tested with LH assay. As with all tests containing monoclonal antibodies, erroneous findings may be obtained from samples taken from patients who have been treated with monoclonal mouse antibodies or who have received them for diagnostic purposes. In rare cases interference due to extremely high titers of antibodies to streptavidin and ruthenium can occur. LH reagent contains additives which minimize these effects. For diagnostic purposes, the LH findings should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.